Skip to main content
. Author manuscript; available in PMC: 2015 Jan 1.
Published in final edited form as: Cancer Immunol Res. 2014 Jan 1;2(1):37–49. doi: 10.1158/2326-6066.CIR-13-0126

Figure 5. Epitopes of CD4+ and CD8+ T cells pre- and post-therapy.

Figure 5

NY-ESO-1-specific CD8+ and CD4+ T cell responses against 20-mer peptides were tested by ELISPOT assays following in vitro stimulation. A, Responses of CD8+ and CD4+ T cells pre-therapy, post-therapy, and at the time of follow-up (FU; 6 months after the last treatment), from patients #03 and #06. For patient #03, the post-treatment time point shown for both CD8+ and CD4+ is day 113. For patient #06, the post-treatment time points shown are d57 and d85 for CD8+ and CD4+, respectively. B, Summary of NY-ESO-1 epitopes recognized by CD8+ or CD4+ T cells. A positive response was defined as a spot count > 50 out of 50,000 cells, and at least > 3× spot count of unpulsed targets.